AARDVARK THERAPEUTICS INC (AARD) Forecast, Price Target & Analyst Ratings
NASDAQ:AARD • US0029421007
5.85 USD
+0.11 (+1.92%)
At close: Mar 6, 2026
5.75 USD
-0.1 (-1.71%)
After Hours: 3/6/2026, 4:41:33 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AARDVARK THERAPEUTICS INC (AARD).
Forecast Snapshot
Consensus Price Target
$33.29
+ 469.04% Upside
Next Earnings Forecast
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$0.85
Revenue Estimate
ChartMill Buy Consensus
87.78%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$33.29
Upside
+ 469.04%
From current price of $5.85 to mean target of $33.29, Based on 18 analyst forecasts
Low
$18.18
Median
$32.64
High
$52.50
Price Target Revisions
1 Month
-0.19%
3 Months
6.57%
Price Target Summary
18 analysts have analysed AARD and the average price target is 33.29 USD. This implies a price increase of 469.04% is expected in the next year compared to the current price of 5.85.
The average price target has been revised upward by 6.57% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.78%
AARD was analyzed by 18 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about AARD.
In the previous month the buy percentage consensus was at a similar level.
AARD was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | BTIG | Maintains | Buy -> Buy |
| 2026-03-02 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-03-02 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2026-03-02 | Stifel | Downgrade | Buy -> Hold |
| 2026-03-02 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2026-03-02 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2026-02-10 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-23 | Oppenheimer | Initiate | Outperform |
| 2025-12-12 | William Blair | Initiate | Outperform |
| 2025-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-07 | BTIG | Initiate | Buy |
| 2025-10-01 | Jones Trading | Initiate | Buy |
| 2025-09-29 | Stifel | Initiate | Buy |
| 2025-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-28 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-30 | HC Wainwright & Co. | Initiate | Buy |
| 2025-05-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-01 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-04-01 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-03-27 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-10 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-10 | RBC Capital | Initiate | Outperform |
| 2025-03-10 | B of A Securities | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$0.85
Revenue Estimate
Revenue Q2QN/A
EPS Q2QN/A
Number of Analysts13
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
1.13%
Next Earnings Summary
AARD is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -0.85 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 2,749.91% | N/A 732.59% | N/A 233.87% | N/A 53.34% | N/A 51.85% | N/A 36.98% | N/A 23.61% | ||||
| EBITDA YoY % growth | -10.253M | -7.318M 28.63% | -22.769M -211.14% | N/A -170.22% | N/A -38.86% | N/A -39.52% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -10.363M | -7.415M 28.45% | -22.785M -207.28% | N/A -180.73% | N/A -39.31% | N/A -35.33% | N/A 17.33% | N/A 87.73% | N/A 747.26% | N/A 128.69% | N/A 85.51% | N/A 45.42% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A -22.48% | N/A -9.33% | N/A 44.12% | N/A 132.73% | N/A 314.58% | N/A 52.85% | N/A 68.22% | N/A 34.33% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.85 | -0.92 -29.58% | -0.97 -46.43% | -0.90 -20.36% | -0.95 -11.02% | -1.24 -35.25% | -1.53 -58.31% | -1.95 -115.82% | -2.37 -150.13% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.462M -105.95% | -20.008M -91.10% | -20.723M -30.76% | -20.935M -18.26% | -22.251M -14.33% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-60.96%
EPS Next 5 Year
22.54%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-73.60%
EBIT Next 5 Year
N/A
AARDVARK THERAPEUTICS INC / AARD Forecast FAQ
What is the price target for AARD stock?
18 analysts have analysed AARD and the average price target is 33.29 USD. This implies a price increase of 469.04% is expected in the next year compared to the current price of 5.85.
Can you provide the upcoming earnings date for AARDVARK THERAPEUTICS INC?
AARDVARK THERAPEUTICS INC (AARD) will report earnings on 2026-03-30.
What are the consensus estimates for AARD stock next earnings?
The consensus EPS estimate for the next earnings of AARDVARK THERAPEUTICS INC (AARD) is -0.85 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for AARDVARK THERAPEUTICS INC stock?
The consensus rating for AARDVARK THERAPEUTICS INC (AARD) is 87.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.